Tag: Glucagon agonist

According to phase 2 clinical trials published in the *New England Journal of Medicine*, individuals taking retatrutide began experiencing reduced appetite and initial metabolic changes within the first 2-4 weeks. This progressive timeline shows how long does retatrutide take to start working for sustained and impactful results.

In a Phase 2 clinical trial, the investigational drug retatrutide demonstrated a remarkable average body weight reduction of up to 24.2% at 48 weeks [1.6.8]. This raises a critical question for the future of metabolic medicine: **why is retatrutide better than tirzepatide?**

In a Phase 2 trial, pemvidutide helped patients achieve significant weight loss while demonstrating class-leading preservation of lean muscle mass. This investigational drug, known as pemvidutide, is a novel dual-agonist peptide with potential applications in obesity, metabolic dysfunction-associated steatohepatitis (MASH), and other metabolic diseases.